Four children with "universally fatal" brain cancer are alive years after an experimental therapy

Biotech & Longevity 5 min 80 sources

A small trial of a cell therapy kept children with incurable brain tumours alive for years — a phase 1 result, not a cure. Plus the FDA starts publishing its drug rejections again, and three big programs die.

Key takeaways

Four children with brain cancers that usually kill within a year are alive years later after an experimental cell therapy — but it was a tiny phase 1 trial with no control group, a hopeful signal, not a proven cure.
The FDA has resumed publishing its drug-rejection letters after a spring pause, making public the reasons drugs fail — so the whole field, not just one company, can learn from them.
Three big drug programs died this week (Alzheimer's, heart disease, Huntington's), a reminder that the rare successes sit on a mountain of quiet, necessary failures.

The most striking biotech result this week came from a small trial that broke no records for size and proved nothing on its own. Four children with brain cancers that normally kill within a year are still alive — some five years on — after an experimental immune therapy [17]. Read carefully, it is not a cure. Read carefully, it is still remarkable.

The children who are still here

Doctors at Children’s National Hospital in Washington DC gave a treatment called TAA T-cell therapy to 33 children and young adults [17]. The idea is to train the patient’s own immune cells — T-cells, the body’s search-and-destroy squad — to recognise proteins found on their tumour, then infuse them back in to hunt it.

The trial deliberately took the worst cases. Most had diffuse intrinsic pontine glioma, or DIPG — a tumour woven into the brain stem that surgeons can’t cut out. Children with DIPG usually live less than a year [17]. One treated child with DIPG is alive more than two years later [17]. Three others had aggressive tumours that had already survived up to 17 rounds of chemotherapy and radiation. Between two and five years after the therapy, all three are alive with no sign of disease [17]. “These children are getting to grow up — it’s truly awesome,” said Gene Hwang, one of the doctors [17].

Now the caveats, because this beat lives on them. It was a phase 1 trial — the first, smallest test in humans, designed to check that a treatment is safe, not to prove it works [17]. There were only 33 patients and no control group, so there’s nothing to compare against [17]. The team doesn’t yet know why it worked for some children and not others [17]. “No one is jumping up and down and saying ‘this is it’ just yet,” the researchers said [17]. A personalised version is now being tested in more patients.

Why the boldest medicine goes to the sickest patients

Notice which cancers this trial chose: the ones with, in one researcher’s words, “nothing else for them” [17]. That is not a coincidence. The deadliest, most hopeless diseases are exactly where the most experimental treatments get tried first — and it’s worth understanding why.

The same logic showed up elsewhere this week. In the Democratic Republic of the Congo, teams raced to launch an Ebola drug trial just six weeks after the outbreak was declared an emergency — a record pace [57]. There is no approved treatment for the strain now circulating, and as of 9 July it had caused 1,792 confirmed cases and 625 deaths [57]. And US researchers reported early excitement — tempered with caution — over a drug for pancreatic cancer, one of the deadliest tumours there is [64].

When the alternative is near-certain death, the maths of risk changes shape. That is the thread running under all of it.

The FDA starts showing its “no” again

A quieter but important shift: the FDA, the US drug regulator, has resumed publishing the letters it sends companies when it rejects a drug [4]. These are called complete response letters — the formal “no,” spelling out exactly why an application failed. For decades they were secret. A company could be turned down and tell the world only that it was “working with the agency.”

Last September the FDA promised to publish these rejections in something close to real time, and released 89 of them [6]. It paused the practice in April after an unnamed drug company petitioned that the letters could expose trade secrets [6][4]. This week it posted 14 more, some dating back to April [4]. The rejections named include an AbbVie botulinum-toxin drug and a cancer-drug combination from Hengrui and Elevar, turned down for the third time [4][6].

Why this matters beyond the paperwork: when the reasons a drug failed stay hidden, every other company is free to walk into the same wall, and investors and patients only hear the company’s spin. When the reasons are public, the whole field can learn from one firm’s failure. A rejection kept private is a lesson no one else gets to have.

Three programs die — the price of the ones that live

For every child still here, there is a long list of things that didn’t work. Three notable programs ended this week.

GSK walked away from a $2.2 billion partnership with Alector after both Alzheimer’s drugs in the deal failed their trials — having paid $700 million upfront [27]. AstraZeneca and Ionis reported that their heart-disease drug failed to beat a placebo in ATTR-CM, a condition where a misshapen protein stiffens the heart muscle [48]. And Roche ended two Huntington’s disease programs, including tominersen, a drug that silences the faulty gene behind the illness [73]. Tominersen has failed before; this was its second collapse [73]. Huntington’s still has no approved medicine that treats its underlying cause, though a gene therapy from the Dutch company uniQure could become the first, with a filing expected this quarter [73].

This is not a run of bad luck. Most drugs that enter human trials fail. The successes we celebrate — the four children — are visible precisely because they are rare, and they sit on a mountain of quiet failures that had to happen first.

The under-covered story: Ebola, and impatience

Back in the DRC, the picture is human before it is scientific. In Bunia, where the virus is spreading, a banana seller and mother of three named Neema Haba put it plainly: “I hope these drug trials proceed quickly. Financially, we are being driven to the brink” [57]. A second trial — testing whether a drug can stop people exposed to Ebola from falling ill — needs about $18 million to run, and has raised $6 million so far [57]. The science can move at record pace and still arrive slower than the people waiting for it.

02 · Lesson · why it matters

The word "experimental" only frightens you if you have something to lose

A risk is never a fixed property of a thing. It is a comparison — and the moment your baseline changes, the same unproven choice flips from reckless to obvious.

The reflex, and the exception

Say the word “experimental treatment” and most people flinch. Untested. Risky. A gamble you’d only take if you were desperate. That flinch is healthy. It has kept people away from a thousand quack cures.

Now look at the four children. Each had a brain cancer that kills within a year, or one that had already shrugged off seventeen rounds of standard treatment. For them, an experimental therapy was not a gamble against safety. It was the only door in the room. Years later, they are still alive.

The reflex and the exception don’t actually disagree. They’re just standing in different places.

Risk is a comparison, not a label

We talk about risk as if it lives inside a thing. This drug is risky. That surgery is dangerous. But a risk is always risk compared to what. Strap into a plane and you accept a small danger — measured against the alternative of not getting where you’re going. Skip the plane and you accept a different one.

An unproven cancer therapy carries real dangers: it might do nothing, it might do harm. Weigh those against a healthy body, and they loom large. Weigh them against a tumour that will kill you by Christmas, and they shrink to almost nothing. The therapy didn’t change. The thing you’re holding it up against did.

This is why the boldest medicine goes to the sickest patients. It isn’t cruelty and it isn’t luck. When the floor is already the worst case, there is very little left to lose — and everything to gain. The deadliest diseases are where the first, riskiest treatments get tried, because those are the only patients for whom the maths makes sense.

The baseline you can’t see

Here is the quiet part. Your sense of what counts as “too risky” is set by a baseline you never chose and rarely notice: the assumption that, left alone, you’ll probably be fine.

For most of us, most of the time, that assumption holds. So it fades into the background and stops feeling like an assumption at all. It just feels like the truth about risk. “Only take the unproven thing if you’re desperate” sounds like plain common sense.

But it’s not a universal truth. It’s the view from a particular seat — the seat of someone with a future to protect. Move to a different seat, where the baseline is death this year, and the same common sense inverts. Not because those people are braver or more reckless. Because they’re doing the same comparison you are, against a different number.

Who trials are built on

There’s a harder edge to this. The whole machinery of medical progress runs on people for whom the floor has already dropped out.

A phase 1 trial — the first test of a treatment in humans — mostly exists to check that something is safe, not that it works. Somebody has to go first, before anyone knows. And the people who go first are, again and again, the ones with nothing left to lose: the terminal, the last-line, the “nothing else for them” cases. The pancreatic-cancer patients. The families in the Ebola ward with no approved drug and a virus in the house.

Every settled, boring, approved treatment your doctor hands you without a second thought was once experimental. It passed through people who took the unproven version because the proven version didn’t exist yet. The rest of us — the healthy, the treatable, the not-yet-sick — are standing downstream of a decision we never had to make, drinking water someone else tested for us.

The failures are part of the same story

That downstream position also hides how much fails. This week, three big drug programs died — for Alzheimer’s, for heart disease, for Huntington’s. The four surviving children are visible precisely because survival is rare; they sit on a mountain of quiet failures that had to happen first.

The same logic is why it matters that a regulator has started publishing its rejections instead of burying them. When the reasons a drug failed stay hidden, the next team walks into the same wall, and the field’s shared baseline of knowledge never rises. A failure everyone can see is a lesson everyone gets. A failure kept secret is a cost paid twice.

What the different seats can and can’t see

So we carry a calibration of risk we didn’t choose, tuned to a life we’re lucky enough to be living, and we mistake it for the fixed truth about what’s dangerous and what’s safe. It isn’t the truth. It’s a reading taken from one position.

The families of those four children read the same instrument and got a different number — not because they lost their judgement, but because the world had moved the baseline under their feet. Neither reading is wrong. Each is honest from where it stands. And no single seat, healthy or dying, gets to see the whole board: how much was risked, how much was lost getting here, whose desperate “yes” made your careful “no” possible.

The next time “experimental” makes you flinch, the flinch is fine. Just remember it’s a comparison — and that somewhere, someone is running the same numbers you are, and reaching, sanely, for the door you’d never touch.

03 · Lab · your turn

The Same Choice, Two Baselines

Weigh one unproven therapy against different prognoses and feel the sensible choice flip as your alternative — not the therapy — changes.

04 · Hope · carry this

Every ordinary treatment your doctor now hands over without a second thought was once someone's desperate experiment. The frightening, unproven thing being tried on the sickest patients today is exactly how tomorrow's safe, boring medicine gets made.